Antipsychotic dose reduction: unclear benefits but certain risks

Stefan Leucht; Irene Bighelli; Spyridon Siafis; Johannes Schneider-Thoma; John M. Davis

doi:10.1016/S2215-0366(23)00308-5

Antipsychotic dose reduction: unclear benefits but certain risks

Stefan Leucht, Irene Bighelli, Spyridon Siafis, Johannes Schneider-Thoma, John M. Davis

Department of Psychiatry and Psychotherapy

Research output: Contribution to journal › Comment/debate

3 Scopus citations

Original language	English
Pages (from-to)	819-821
Number of pages	3
Journal	The Lancet Psychiatry
Volume	10
Issue number	11
DOIs	https://doi.org/10.1016/S2215-0366(23)00308-5
State	Published - Nov 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S2215-0366(23)00308-5

Cite this

@article{efc8a19d94504425807cb37921d97000,

title = "Antipsychotic dose reduction: unclear benefits but certain risks",

author = "Stefan Leucht and Irene Bighelli and Spyridon Siafis and Johannes Schneider-Thoma and Davis, {John M.}",

year = "2023",

month = nov,

doi = "10.1016/S2215-0366(23)00308-5",

language = "English",

volume = "10",

pages = "819--821",

journal = "The Lancet Psychiatry",

issn = "2215-0366",

publisher = "Elsevier Ltd.",

number = "11",

}

TY - JOUR

T1 - Antipsychotic dose reduction

T2 - unclear benefits but certain risks

AU - Leucht, Stefan

AU - Bighelli, Irene

AU - Siafis, Spyridon

AU - Schneider-Thoma, Johannes

AU - Davis, John M.

PY - 2023/11

Y1 - 2023/11

UR - http://www.scopus.com/inward/record.url?scp=85173887678&partnerID=8YFLogxK

U2 - 10.1016/S2215-0366(23)00308-5

DO - 10.1016/S2215-0366(23)00308-5

M3 - Comment/debate

AN - SCOPUS:85173887678

SN - 2215-0366

VL - 10

SP - 819

EP - 821

JO - The Lancet Psychiatry

JF - The Lancet Psychiatry

IS - 11

ER -

Antipsychotic dose reduction: unclear benefits but certain risks

UN SDGs

Access to Document

Other files and links

Cite this